

MolMed appoints Professor Robert Kerbel to its Scientific Advisory Board

Milan (Italy), 16 December 2008 - MolMed S.p.A. (Milan:MLM) is pleased to announce that Professor Robert Kerbel has joined the Company's Scientific Advisory Board (SAB). Robert Kerbel is an internationally renowned scientist in the field of innovative cancer therapies, and his appointment strengthens even further the expertise of the SAB. The SAB contributes significantly to MolMed's decisions on its R&D pipeline by assessing the Company's projects and results. "Professor Kerbel's scientific excellence in a field at the core of our therapeutic focus will allow us to further optimise the full development of our most advanced investigational new anticancer therapeutics, with particular reference to the vascular targeting agent NGR-hTNF", commented Claudio Bordignon, Chairman and CEO of MolMed, as well as Chairman of MolMed's SAB. "With his expertise, we will also have even stronger guidance when evaluating research options to feed our anticancer pipeline."

Robert Kerbel is Senior Scientist in the Molecular and Cellular Biology Research Program at the Sunnybrook Health Sciences Centre in Toronto (Canada), Professor in the Departments of Medical Biophysics and of Laboratory Medicine & Pathobiology at the University of Toronto, and Canada Research Chair in Tumour Biology, Angiogenesis and Antiangiogenic Therapy. He has worked for over 30 years in tumour biology research, and since 1990 its main research focus has been in the field of tumour angiogenesis. His most noteworthy contributions include the development of innovative therapeutic and biomarker strategies for antiangiogenic drugs, elucidating mechanism of VEGF-pathway targeting drugs, uncovering the role of oncogenes in the tumour angiogenic switch, and the development of new models of advanced metastatic disease in mice. His work is highly translational, with direct impact on the start of several clinical trials around the world.

MolMed's Scientific Advisory Board combines the knowledge and experience of leading international experts in the field of cancer. In addition to its Chairman Claudio Bordignon and the new member Robert Kerbel, it includes: Carl-Henrik Heldin, Branch Director of the Ludwig Institute for Cancer Research Research in Uppsala (Sweden), and Professor of Molecular and Cell Biology at Uppsala University; Alberto Sobrero, Head of the Medical Oncology Unit at the clinical centre *Ospedale San Martino* in Genova (Italy); Didier Trono, Deputy Director of the Swiss National Science Foundation's "Frontiers in Genetics" area, and Professor and Dean of the School of Life Sciences at the *École Polytechnique Fédérale* in Lausanne (Switzerland).

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes two novel therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III in high-risk acute leukaemias; and NGR-hTNF, a novel vascular targeting agent (VTA), in Phase II in four different indications (colorectal, small-cell lung and liver cancers, and mesothelioma). MolMed's clinical pipeline is supported by a broad portfolio of therapeutic candidates. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The company's shares (Milan:MLM) are listed at the Milan Stock Exchange, on the Standard segment (class I) of the MTA managed by Borsa Italiana.

For further information, please contact:

Holger Neecke
Director Business Development, IR
MolMed S.p.A.
phone: +39 02 21277.205
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

Elena Lungagnani
Communication Manager
MolMed S.p.A.
phone: +39 02 21277.207
fax: +39 02 21277.325
e-mail: media.relations@molmed.com